ES2184270T3 - Nuevos compuestos. - Google Patents

Nuevos compuestos.

Info

Publication number
ES2184270T3
ES2184270T3 ES98924705T ES98924705T ES2184270T3 ES 2184270 T3 ES2184270 T3 ES 2184270T3 ES 98924705 T ES98924705 T ES 98924705T ES 98924705 T ES98924705 T ES 98924705T ES 2184270 T3 ES2184270 T3 ES 2184270T3
Authority
ES
Spain
Prior art keywords
new compounds
hyperproliferating
proliferating
autoimmune
prophylactic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98924705T
Other languages
English (en)
Inventor
David Cheshire
Andrew Cooke
Martin Cooper
David Donald
Mark Furber
Matthew Perry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2184270T3 publication Critical patent/ES2184270T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Liquid Crystal (AREA)

Abstract

La invención se refiere a nuevos compuestos de fórmula (I), en la que R, R1, R2 y R3 tienen el significado dado en la descripción. El compuesto (I) es útil en el tratamiento (profiláctico) de enfermedades autoinmunes, inflamatorias, proliferantes e hiperproliferantes y enfermedades inmunológicamente inducidas incluyendo el rechazo de órganos o tejidos transplantados y el síndrome de inmunodeficiencia adquirido (SIDA).
ES98924705T 1997-05-28 1998-05-18 Nuevos compuestos. Expired - Lifetime ES2184270T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702001A SE9702001D0 (sv) 1997-05-28 1997-05-28 Novel compounds

Publications (1)

Publication Number Publication Date
ES2184270T3 true ES2184270T3 (es) 2003-04-01

Family

ID=20407123

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98924705T Expired - Lifetime ES2184270T3 (es) 1997-05-28 1998-05-18 Nuevos compuestos.

Country Status (28)

Country Link
US (2) US6180635B1 (es)
EP (1) EP0991653B1 (es)
JP (1) JP2002500666A (es)
KR (1) KR100561988B1 (es)
CN (1) CN1122037C (es)
AT (1) ATE226205T1 (es)
AU (1) AU723708B2 (es)
BR (1) BR9809481A (es)
CA (1) CA2289509C (es)
CZ (1) CZ297536B6 (es)
DE (1) DE69808765T2 (es)
DK (1) DK0991653T3 (es)
EE (1) EE04018B1 (es)
ES (1) ES2184270T3 (es)
HU (1) HU226627B1 (es)
ID (1) ID28432A (es)
IL (2) IL132763A0 (es)
IS (1) IS1983B (es)
NO (1) NO323752B1 (es)
NZ (1) NZ500853A (es)
PL (1) PL199567B1 (es)
PT (1) PT991653E (es)
RU (1) RU2225410C2 (es)
SE (1) SE9702001D0 (es)
SK (1) SK283589B6 (es)
TR (1) TR199902904T2 (es)
UA (1) UA61111C2 (es)
WO (1) WO1998054190A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GB9819382D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
AU2001252825A1 (en) * 2000-05-04 2001-11-12 Astrazeneca Ab Thieno(2,3-d)pyrimidinediones and their use as pharmaceuticals
GB2361917A (en) * 2000-05-04 2001-11-07 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones
GB2363377B (en) * 2000-06-14 2004-06-09 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones and therapeutic uses thereof
MXPA03004926A (es) * 2001-02-14 2005-02-14 Warner Lambert Co Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas.
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
RU2374236C2 (ru) * 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
WO2004002481A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300117D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel Compounds
RU2332420C2 (ru) * 2003-01-17 2008-08-27 Астразенека Аб Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания
RU2386622C9 (ru) * 2004-01-06 2021-04-21 Ново Нордиск А/С Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы
CA2614518A1 (en) * 2005-07-08 2007-01-18 Novo-Nordisk A/S Dicycloalkyl urea glucokinase activators
EP1904438B1 (en) * 2005-07-08 2012-02-29 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
EP2377856A1 (en) * 2005-07-14 2011-10-19 Novo Nordisk A/S Urea glucokinase activators
EP1989210A2 (en) * 2006-03-02 2008-11-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
CN101186612B (zh) * 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
WO2008070529A2 (en) * 2006-12-01 2008-06-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
JP2010515701A (ja) * 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
US8318778B2 (en) * 2007-01-11 2012-11-27 Novo Nordisk A/S Urea glucokinase activators
EP2008656A1 (en) * 2007-06-28 2008-12-31 Bergen Teknologioverforing AS Compositions for the treatment of hyperphenylalaninemia
JP2012521406A (ja) * 2009-03-23 2012-09-13 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１調節因子としてのフロピリミジンジオン誘導体
HUE037444T2 (hu) * 2011-11-11 2018-09-28 Gilead Apollo Llc ACC inhibitorok és azok felhasználása
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
SG11201602397XA (en) * 2013-10-07 2016-05-30 Bayer Pharma AG Cyclic thienouracil-carboxamides and use thereof
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
EP3379933B1 (en) 2015-11-25 2023-02-15 Gilead Apollo, LLC Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine
BR112018010453B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Compostos triazólicos inibindores de acetil coa carboxilase (acc)
MX2018006288A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc tipo ester y usos de los mismos.
WO2017091600A1 (en) 2015-11-25 2017-06-01 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
CA3172549A1 (en) 2016-03-02 2017-09-08 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
SG11201902588PA (en) 2016-09-23 2019-05-30 Bayer Ag N3-Cyclically Substituted Thienouracils And Use Thereof
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002432A1 (en) * 1987-09-16 1989-03-23 Taiho Pharmaceutical Company, Limited Thienopyrimidine derivatives
TW276256B (es) * 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
FR2750862B1 (fr) * 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques

Also Published As

Publication number Publication date
HU226627B1 (en) 2009-05-28
IL132763A0 (en) 2001-03-19
PT991653E (pt) 2003-02-28
AU7680898A (en) 1998-12-30
CN1264382A (zh) 2000-08-23
CA2289509C (en) 2007-10-02
ATE226205T1 (de) 2002-11-15
EP0991653A1 (en) 2000-04-12
BR9809481A (pt) 2000-06-20
KR100561988B1 (ko) 2006-03-17
IS1983B (is) 2005-01-14
HUP0003355A3 (en) 2003-03-28
CZ420199A3 (cs) 2000-07-12
NO323752B1 (no) 2007-07-02
HUP0003355A2 (hu) 2001-02-28
WO1998054190A1 (en) 1998-12-03
DE69808765D1 (de) 2002-11-21
PL337126A1 (en) 2000-07-31
ID28432A (id) 2001-05-24
SK151399A3 (en) 2000-05-16
UA61111C2 (uk) 2003-11-17
NO995810D0 (no) 1999-11-26
CA2289509A1 (en) 1998-12-03
NO995810L (no) 2000-01-27
CN1122037C (zh) 2003-09-24
IL132763A (en) 2007-03-08
CZ297536B6 (cs) 2007-01-03
NZ500853A (en) 2001-05-25
EE04018B1 (et) 2003-04-15
DE69808765T2 (de) 2003-07-24
TR199902904T2 (xx) 2000-06-21
KR20010013107A (ko) 2001-02-26
PL199567B1 (pl) 2008-10-31
JP2002500666A (ja) 2002-01-08
IS5264A (is) 1999-11-23
RU2225410C2 (ru) 2004-03-10
SK283589B6 (sk) 2003-10-07
SE9702001D0 (sv) 1997-05-28
US6180635B1 (en) 2001-01-30
US6342502B1 (en) 2002-01-29
AU723708B2 (en) 2000-09-07
EE9900539A (et) 2000-06-15
DK0991653T3 (da) 2003-01-06
EP0991653B1 (en) 2002-10-16

Similar Documents

Publication Publication Date Title
ES2184270T3 (es) Nuevos compuestos.
NL350077I2 (nl) Cyprosulfamide
AR001440A1 (es) Nuevos taxoides, su preparación y composiciones farmacéuticas que los contienen.
DE69124371T2 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
HUP0004592A2 (hu) VCAM-1 expresszió gátlására alkalmas vegyületek és eljárások
ATE242213T1 (de) Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
DE69503647D1 (de) Aminoheterocyclische derivate als antithrombotische oder antikoagulierende mittel
DK0772610T3 (da) Dihydrobenzofuraner
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
ES2031523T3 (es) Agentes diureticos de glutaramida espiro-sustituida.
DK1200418T3 (da) Nematodicide trifluorbutener
EA200200374A1 (ru) Производные хинолилпропилпиперидина, их получение и содержащие их композиции
NZ325449A (en) Naphthyl-substituted benzimidazole derivatives as anticoagulants
BR0116519B1 (pt) cartucho de hemodiafiltraÇço/hemofiltraÇço de diluiÇço intermediÁria.
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
ES2134777T3 (es) Nuevos compuestos de sulfonilo.
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
ES2142490T3 (es) Ciclopeptolidos.
NO930234D0 (no) Antikoagulerende midler
SE9603285D0 (sv) New compounds
ES2108004T3 (es) Nuevas alquil piperidinas sustituidas y su empleo como inhibidores de la sintesis de colesterol.
EA200100152A1 (ru) Замещенные пиперазиноны и их терапевтическое применение
EA199901072A1 (ru) Фунгицидная смесь
EA200100151A1 (ru) Производные пиперазинона и их применение
EA199901065A1 (ru) Фунгицидные смеси